FDA Inspection 1257822 — Hangzhou ApexTide Biomedical Technology Co., Ltd.
The FDA completed an inspection of Hangzhou ApexTide Biomedical Technology Co., Ltd. on Nov 1, 2024 in Hangzhou. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Nov 1, 2024
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Hangzhou (China)